Achillion Pharmaceuticals Inc (ACHN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
58
About the Report
About the Report
Summary
Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients with rare diseases. It is developing oral antiviral therapy for chronic hepatitis C (HCV) and a platform of potent and specific complement inhibitors. Achillion intends to develop and commercialize factor D inhibitors for rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD) and chronic obstructive pulmonary disease (COPD). Achillion is headquartered in New Haven, Connecticut, the US.
Achillion Pharmaceuticals Inc (ACHN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Achillion Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Achillion Pharma Enters into Licensing Agreement with Ora 11
Equity Offering 12
Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12
Achillion Pharma to Raise Funds through Secondary Offering of Shares 13
Achillion Pharma Raises USD225 Million in Private Placement of Shares 14
Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16
Achillion Pharma Completes Public Offering Of Shares For USD 142 Million 17
Achillion Pharma Completes Private Placement Of Shares For USD 42 Million 19
Achillion Pharmaceuticals Inc-Key Competitors 20
Achillion Pharmaceuticals Inc-Key Employees 21
Achillion Pharmaceuticals Inc-Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 08, 2018: Achillion reports second quarter 2018 financial results 23
May 02, 2018: Achillion Reports First Quarter 2018 Financial Results and Management Transition 25
Feb 22, 2018: Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results 27
Nov 01, 2017: Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs 29
Aug 08, 2017: Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor 30
May 04, 2017: Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs 33
Feb 23, 2017: Achillion Reports 2016 Fourth Quarter and Year-End Financial Results 35
Corporate Communications 37
Sep 10, 2018: Achillion Pharmaceuticals names Paul Firuta Chief Operating Officer 37
Aug 21, 2018: Achillion Pharmaceuticals names Dr. Steven Zelenkofske as Chief Medical Officer 38
Aug 15, 2018: Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer 39
Sep 11, 2017: Achillion Announces Strengthening of Management Team 40
Jul 10, 2017: Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change 41
Product News 42
09/11/2017: Janssen to Discontinue Hepatitis C Development Program 42
02/26/2018: Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy 43
Product Approvals 44
Nov 06, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 44
Clinical Trials 45
Jul 10, 2018: Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D 45
Dec 20, 2017: Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D 46
Dec 18, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study 47
Nov 14, 2017: Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G 48
Nov 01, 2017: Achillion Provides Update on ACH-4471 50
Nov 01, 2017: Achillion Provides Update on ACH-5228 52
Oct 23, 2017: Data on the clinical activity of simeprevir in combination with AL-335 and odalasvir (JNJ-4178) presented at the 2017 Liver Meeting 53
Apr 24, 2017: Update on the development of simeprevir as part of the triple combination with AL-335 and odalasvir (JNJ-4178) 54
Apr 22, 2017: Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178 55
Apr 06, 2017: Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria 56
Apr 06, 2017: New data for simeprevir will be presented at EASL's International Liver Congress 2017 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List of Figure
List of Figures
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achillion Pharma Enters into Licensing Agreement with Ora 11
Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12
Achillion Pharma to Raise Funds through Secondary Offering of Shares 13
Achillion Pharma Raises USD225 Million in Private Placement of Shares 14
Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16
Achillion Pharma Completes Public Offering Of Shares For USD 142 Million 17
Achillion Pharma Completes Private Placement Of Shares For USD 42 Million 19
Achillion Pharmaceuticals Inc, Key Competitors 20
Achillion Pharmaceuticals Inc, Key Employees 21
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.